Frontiers in Immunology

This study, drawing data from Kuwait and Qatar, evaluates the efficacy of pioglitazone, a strong insulin sensitizer with anti-inflammatory properties, in improving the clinical outcomes of patients with type 2 diabetes admitted with moderate-severe COVID-19.

Journal Article